A Randomised Double Blind (Sponsor Unblinded), Single and Repeat Ascending Dose First Time in Human Study in Healthy Subjects, Cold Urticaria and Chronic Spontaneous Urticaria Subjects to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264

This First Time in Human (FTIH) study, which will be performed in three parts, is designed to
investigate the safety, local tolerability, pharmacokinetics and pharmacodynamics after
single and repeat topical applications of up to 2 strengths of GSK2646264 and corresponding
placebo within the same subject, in healthy adult subjects (Part A), subjects with cold
urticaria (CU, Part B) and subjects with chronic spontaneous urticaria (CsU, Part C). The
study will also measure short term effects of GSK2646264 on the number and size of weals in
subjects with CsU, and in healthy subjects and subjects with CU following provocation tests.